{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:21:50Z","timestamp":1783066910976,"version":"3.54.6"},"reference-count":14,"publisher":"Galenos Yayinevi","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turk J Phys Med Rehab"],"accepted":{"date-parts":[[2022,1,29]]},"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) is a novel virus that primarily involves the respiratory system. Due to the COVID-19 pandemic, an extensive vaccination program is underway worldwide. Herein, we present a 68-year-old woman with paresthesia of both hands associated with gait instability, which started three to four days after receiving the second dose of Oxford\/AstraZeneca vaccine against the COVID-19 infection. The acute inflammatory demyelinating polyradiculoneuropathy subtype of the Guillain-Barre syndrome, which is the most common subtype, was diagnosed. Regardless of the beneficial effects of the vaccines, this case report aimed to evaluate their severe complications, such as Guillain-Barre syndrome, to reduce their occurrence in the future.<\/jats:p>","DOI":"10.5606\/tftrd.2022.9984","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T06:11:05Z","timestamp":1659334265000},"page":"295-299","source":"Crossref","is-referenced-by-count":11,"title":["A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination"],"prefix":"10.4274","volume":"68","author":[{"given":"Hanieh","family":"Bazrafshan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Sadat Mohamadi Jahromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhaneh","family":"Parvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","reference":[{"key":"ref-1","doi-asserted-by":"crossref","unstructured":"Asadi-Pooya AA. Seizures associated with coronavirus infections. Seizure 2020;79:49-52.","DOI":"10.1016\/j.seizure.2020.05.005"},{"key":"ref-2","unstructured":"Hatamnejad MR, Fallah Tafti F, Abdi ardekani A, Sadeghi Boogar S, Bazrafshan H. Coronary thrombosis in a patient with COVID-19 who was on anticoagulant therapy. Int Cardio Res J 2021;15:e114520"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA, et al. Guillain-Barr\u00e9 syndrome following ChAdOx1-S\/nCoV-19 vaccine. Ann Neurol 2021;90:312-4.","DOI":"10.1002\/ana.26143"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"Ogbebor O, Seth H, Min Z, Bhanot N. Guillain-Barr\u00e9 syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association. IDCases 2021;24:e01143.","DOI":"10.1016\/j.idcr.2021.e01143"},{"key":"ref-5","doi-asserted-by":"crossref","unstructured":"Introna A, Caputo F, Santoro C, Guerra T, Ucci M, Mezzapesa DM, et al. Guillain-Barr\u00e9 syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association? Clin Neurol Neurosurg 2021;208:106887.","DOI":"10.1016\/j.clineuro.2021.106887"},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, et al. Guillain-Barr\u00e9 syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol 2021;90:315-8.","DOI":"10.1002\/ana.26144"},{"key":"ref-7","doi-asserted-by":"crossref","unstructured":"Hasan T, Khan M, Khan F, Hamza G. Case of Guillain- Barr\u00e9 syndrome following COVID-19 vaccine. BMJ Case Rep 2021;14:e243629.","DOI":"10.1136\/bcr-2021-243629"},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barr\u00e9 syndrome: Pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014;10:469-82.","DOI":"10.1038\/nrneurol.2014.121"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"Kaida K. Guillain-Barr\u00e9 syndrome. Adv Exp Med Biol 2019;1190:323-31.","DOI":"10.1007\/978-981-32-9636-7_20"},{"key":"ref-10","doi-asserted-by":"crossref","unstructured":"Khatoon F, Prasad K, Kumar V. Neurological manifestations of COVID-19: Available evidences and a new paradigm. J Neurovirol 2020;26:619-30.","DOI":"10.1007\/s13365-020-00895-4"},{"key":"ref-11","doi-asserted-by":"crossref","unstructured":"Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, et al. Association between Guillain-Barr\u00e9 syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: A meta-analysis. Lancet 2013;381:1461-8.","DOI":"10.1016\/S0140-6736(12)62189-8"},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus 2021;13:e13426.","DOI":"10.7759\/cureus.13426"},{"key":"ref-13","doi-asserted-by":"crossref","unstructured":"Patel SU, Khurram R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep 2021;14:e242956.","DOI":"10.1136\/bcr-2021-242956"},{"key":"ref-14","doi-asserted-by":"crossref","unstructured":"McKean N, Chircop C. Guillain-Barr\u00e9 syndrome after COVID-19 vaccination. BMJ Case Rep 2021;14:e244125.","DOI":"10.1136\/bcr-2021-244125"}],"container-title":["Turkish Journal of Physical Medicine and Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.ftrdergisi.com\/uploads\/pdf\/pdf_4370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.ftrdergisi.com\/uploads\/pdf\/pdf_4370.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:08:01Z","timestamp":1783066081000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ftrdergisi.com\/uploads\/pdf\/pdf_4370.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.5606\/tftrd.2022.9984","relation":{},"ISSN":["2587-1250"],"issn-type":[{"value":"2587-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}